Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You wanna blame me for that b/c of this post 2 months ago?!????
I posted "on watch", never invested a single dollar b/c RS usually bring a lot of harm.
Even banned it from my WL weeks ago... But this still has a legit chance to become a serious company, welcome to "biotech land".
Of course this POS has cost me $15K I know that's not much but WTF
Still in this?
I just saw where you posted on ctix that on the 17th of this month you got another 50000 shares, how many do you have and obviously by your posts recently you must want another 500000. Why bash, just buy.
You obviously have more money than God
Need a landscaper, cook, fishing guide?
Did you forget your deodorant again?
Same story for me on dndn. I bought before their results and sold for $5 or $6 saw it go to 50s
I missed acad same way
I traded DNDN and made a triple, I was shocked when after I happily cashed out it went up another forty dollars. I bought 5000 Nvgn at ave. $2.03 past week. Looking at ARTH for a trade, but not sure, Strik
Most saw it coming. It may end like dendreon
Glad I didn't venture into the spiderweb called MNKD. Strik
Not sure about poet. Now they have to prove something or its done.
Will look into this one.
Mannkind, its a crap shoot. It's not selling too well.
I feel and hope we see a pump up to at least $1.50 by March. Then I sell 90% of my holding . As far as Nvgn goes , I've been successfully trading it since the 90s and I see a double coming by end of March. And I agree , something ain't right with those Bozos on agora , but I feel confident I can make some good green end of first quarter 2016. What you think is MNKD under $1.50? May be a trade pr is it over? Strik
BTW,I got out if poet months ago
I think those guys pump n sell. And then repeat.
I wouldn't last 10 seconds on Agora.. I'd be quickly banned by the Canadiens dictators who run the show. God bless America,Strik
Smartphone chips? Lol
Still reading agora, I see
I wonder how much $$ a buyout would really cost the buyer per share
I like that one too...ey say end of 2016 it should be ready to make revenues,hopfully huge ones,i hope they start with the phones chips first unless theres a bigger market on others
I still feel Poet is going to make us rich. I'm holding well over 100K under $1 We should know a lot more come mid January
probably good to sell the rip your base and see what happends with the excess,hopefully it means good $$ down the road,ive my eye on this and ct-x
Very hard near impossible to buy out an Aussie company. Nvgn should have no problem getting to Phase3 At that point share price will be a lot higher. In my opinion and I will do this is take my money I put in out and let the rest ride. Nvgn would be very smart to partner by Phase 3 cause you never know at Phase 3 what will happen and most fail ,Strik. P.S. Happy Thanksgiving
if this works as hoped it has potential to make good money or bought out at a good price
Phase one by March 2016 Phase 2 by beginning of 2017. P
how long til phase 2 then commercialization later on
Alla. Alla. Poooooped. Carmalla. Hole. Corn
Bee bloyoo bing bong.
Dang. 'Nother game?
Tong. Tong
Ting. Ting.
Novogen Announces the Chairman's Address at the Company's General Meeting
PR Newswire Novogen Ltd
10 hours ago
????
SYDNEY, June 24, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) announced today the Chairman's Address at the Company's General Meeting. Full text follows:
Dear Shareholders,
The Company is in a solid financial position. With $45M in cash, and the very real prospect of another $33M by the end of the year via short-term warrants, our shareholders have given the Company the opportunity it asked for to prove the merit of its two technology platforms.
Novogen has a boldly ambitious objective… to bring both of our technology platforms together in a complementary way to provide the most effective level of anti-cancer therapy across most forms of cancer yet achieved.
What we are striving for goes well beyond the modest levels (average 5 months) of survival benefit achieved over the past 15 years with targeted chemotherapies such as Herceptin and Avastin, and the low (about 20%) response rates in certain cancer types achieved with the current crop of immuno-oncology drugs despite high rates of debilitating side-effects.
Our target is durable remission across most forms of cancer for most patients; where cancer is reduced to the same status as any other degenerative disease, such as rheumatoid arthritis.
After relying on cytotoxic chemotherapy to do the heavy-lifting in cancer therapy for the past 40 years, much of the pharmaceutical world has gone off in search of new forms of therapy such as cancer vaccines, gene therapy and gene silencing, driven by the fact that cytotoxic chemotherapy appears to have hit a wall:
with little or no effect in many forms of cancer;
with individual patient response rates varying enormously;
with high rates of toxicity limiting dosages to sub-optimal levels;
with most cases of malignant cancer relapsing even where there is an initial response;
with tumors readily developing resistance to cytotoxic drugs.
Cytotoxic chemotherapy is working… Just not very well.
Combine this with the fact that no new significant cytotoxic drug has come to market in the last 20 years, and the search for alternative forms of chemotherapy becomes rational.
Novogen believes that there is another more rational and more practical approach. And that is to make cytotoxic chemotherapy WORK… Not just work better… But to make it work the way we would want it to.
Take the case of a man with metastatic castrate-resistant prostate cancer. His remaining approved option is the cytotoxic drug, docetaxel. He has a 30% chance of responding, with that response delivering on average about a 6-8 month increase in survival. That means that 7 out of 10 men treated with docetaxel get no benefit, despite still getting significant adverse side-effect of therapy.
Our aim is to use our two technologies to increase both the response rate and the average duration of response to something far more meaningful. Prostate cancer is one of the clinical indications we have in mind, but the point being made here is that regardless of the indications, there is substantial room for improvement.
With the level of funding we now have behind us, we now have the means to get into the clinic to test that belief.
I don't need to remind shareholders that an investment in biotechnology is binary… It either works or it doesn't... There isn't much in-between. The difference between Novogen and the majority of other biotech companies is that a positive outcome with either of the Novogen technology platforms could transform chemotherapy. Our technologies are not intended to treat a subset of patients with one particular form of cancer; they are meant to treat most patients with most forms of cancer.
So, to the specifics of what we are doing about reaching this goal.
Starting with Anisina. We made an announcement this morning about this drug candidate. We described how well it performed in mice bearing human melanoma tumors, significantly slowing the growth of a highly aggressive tumor. The drug worked equally well when given orally or intravenously. That was the trigger to bring Anisina into the clinic in 2016, with an enrolment target date of 2Q16.
This will be a standard first-in-man Phase 1 study using patients with a variety of cancers. This clinical study, like most of our planned Phase 1 studies, will be conducted in Australia. The Australian Government's 45 cents in the dollar R&D Rebate Scheme makes conducting clinical studies in Australia highly cost-effective. Some Phase 1 studies will be conducted under an IND in the US, and for all pipeline drugs, all subsequent studies beyond Phase 1 will involve US sites. But where possible, we will be starting in Australian hospitals.
The Phase 1 study will see Anisina being given intravenously as a monotherapy to patients with a broad range of cancers who are being treated on a salvage basis. The compound's safety profile, the highest dose that we can safely administer, and its pharmacokinetic and pharmacodynamics characteristics will all be monitored.
In a parallel program, Anisina also is coming into the clinic for the treatment of solid cancers in children, particularly neuroblastoma. That study will be conducted in both the US and Australia, and is something that we will be explaining in more detail shortly. Suffice to say at this point, that the prospect of being able to offer cytotoxic chemotherapy to young children with a reduced prospect of leaving them with a lifetime's legacy of serious developmental side-effects is of major interest.
Now on to Cantrixil. This is the first of our oncology pipeline that will enter the clinic. Late this year or early next year is when the Phase 1 trial is expected to open. That date is largely in the hands of the hospital ethics committees that will be reviewing the clinical trial protocol that we hope to have lodged in October 2015.
Cantrixil is the product being developed by CanTx Inc, our joint venture company with Yale University. This has been developed as a purpose-built, intra-cavity chemotherapy. The three target cavities are the peritoneal cavity, the pleural cavity and the bladder. Cancers of these cavities are difficult to treat because of the difficulty in achieving meaningful drug levels within the cavity via the bloodstream. And instilling cytotoxic drugs directly into these cavities is an option, but not widely used because of the high risk of damage to healthy tissues.
The ultimate primary goal of Cantrixil is first-line therapy for patients with any cancer arising in the abdominal cavity, but ovarian cancer in particular. The rationale of Cantrixil is to deliver high doses of TRXE-002 where they are needed to track down and kill the tumor-initiating cells that are spreading out from the primary cancer and which are responsible for the multitude of secondary cancers that eventually become so difficult to treat. This is the scenario that the Yale animal model of ovarian cancer was designed to replicate and in which Cantrixil proved to be so effective.
We will move Cantrixil in that setting just as soon as we can. But for the moment, we are obliged to test an experimental drug in patients who have no standard treatment options remaining. And that means using patients with late-stage abdominal cancers. For many of these heavily pre-treated patients, Cantrixil will be at least their 8th -12th line of chemotherapy.
But rather than just using these patients as a necessary stepping stone to eventually testing in 1st line therapy, our oncology advisors raised the possibility that we had developed a product that might offer clinical benefit for a large cohort of cancer patients for whom no effective current therapies exist. These are patients with late-stage cancers involving the peritoneal and pleural cavities where the presence of a large tumor load has resulted in the accumulation of large volumes of fluid. In the case of the abdomen this is known as malignant ascites and in the case of the chest, malignant pleural effusion.
We are starting with malignant ascites. Management of these patients is palliative. It generally involves regular removal of the fluid by a process known as paracentesis. This serves only to make patients as comfortable as possible in their final months. Cantrixil will be infused into the peritoneal cavity of patients following paracentesis and the modest marker of any clinical benefit will be our ability to extend the interval between paracentesis.
And lastly to TRXE-009. This drug candidate came off the drawingboard as a potential treatment for primary brain cancer, but has grown to become our general-purpose product intended to treat all forms of cancer.
The brain cancer focus came from early in vitro studies showing a high level of killing of glioblastoma cells, including glioblastoma stem cells, followed by the same level of activity against a form of pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG).
We then set about developing a strategy to ensure that we could deliver TRXE-009 across the blood-brain barrier at the sort of levels required to kill cancer cells. That led to the development of a proprietary lipid nanoparticle delivery system that we are satisfied will meet that objective. The status of this project is that we currently have engaged a consultant company to optimize this construct in order to facilitate its large-scale manufacture. We anticipate that process taking another several months, at which point we will commence the path into the clinic.
I am not going to speak here of Operation Jacob Hope, a catch-all program that is looking at the application of our super-benzopyran technology platform to non-oncology indications. Time doesn't permit that, but I can report that you will be hearing more of this exciting series of drug development programs in the months ahead.
I want to finish by acknowledging that none of this is possible without two groups of people.
The first group is the Novogen staff. It starts with Andrew Heaton who made the rebirth of Novogen possible by his discovery of the super-benzopyran technology platform. Andrew leads a team of chemists who come up with the design of new molecules that is the core of this Company's asset -- its intellectual property in the form of its growing patent portfolio. David Brown, our CSO, then has the task of converting that asset into practice, and the team that David leads are among the finest and most dedicated scientists it has been my pleasure to work with. Finally, our hard-working COO / CFO, Cristyn Humphries who provides the infrastructure to make all of this possible.
The second group is you, the shareholders. You willingness to entrust us with your money in my view ranks with our IP as our two greatest assets.
We have a mighty big mountain ahead of us to climb. There will be the inevitable challenges along the way, but with patience and perseverance I have no doubt we will get there in the end. The next 2 years are going to be anything but dull. Enjoy the ride.
Yours faithfully,
Dr Graham Kelly
Dr K (NVGN CEO) on Kudlow radio Saturday Nite @7
But stock crumbled?
New SEC form 6-K filed detailing TRXE-009 ability to cross blood brain barrier.
Drugs will have no problem and look very promising through phase one and phase two.Once phase 3 commences sell shares to get initial investment back and a profit then if you want , let the rest ride. I'LL be long gone before results of phase 3 are announced.
when will it happen? I wonder what the pps will be in 5 years from now
Anisina plus CTIX's Kevetrin equals cure for cancer
Studies Confirm TRXE-009 Kills Paediatric Brain Cancer Cells
http://hotcopper.com.au/threads/ann-studies-confirm-trxe-009-kills-paediatric-brain-cancer-cells.2511591/?post_id=15239572#.VUvwKGDey9Y
Novogen Completes the Private Placement of Equity
http://finance.yahoo.com/news/novogen-completes-private-placement-equity-073200143.html
SYDNEY, April 29, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Novogen or Company), announced today that it has completed the placement to US institutional investors of 51,750,000 ordinary shares, raising a total of $15,525,000 (before costs), as previously announced to the market on 21 April 2015.
Subject to Shareholder approval, the Company will issue 51,750,000 unlisted options exercisable at $0.30 within 6 months from the date of issue and 25,875,000 unlisted options exercisable at $0.40 within 5 years from the date of issue.
Dr Graham Kelly, Novogen group CEO and Executive Chairman, said, "This is the first of a three-step process that has been designed to deliver the financial security that the Company needs to commit to a substantial growth strategy. The second step will see the Company complete a pro-rata, non-renounceable Rights Issue offering in early June, which the Company believes will be fully subscribed, bringing its cash position mid-year to about $44M."
"The third step involves the tranche of options with a 6-month exercise term, that are intended to take advantage of current strong market sentiment for the biotech sector, along with an anticipated strong news flow over the remainder of this year following the ramping up of the Company's broad R&D programs."
"We now have certainty and the means to grow into the extraordinary opportunity that our two drug technology platforms have presented us with," Kelly said.
The funds will be applied to bringing a pipeline of 3 oncology drugs (Cantrixil, Trilexium, Anisina) through the clinic to the point intended to test their ability to provide a meaningful clinical benefit to patients with abdominal cancers (malignant ascites), adult and paediatric brain cancers, neuroblastoma, malignant melanoma and castrate-resistant prostate cancer. In the non-oncology space, the programs of ulcerative colitis, repair of brain and spinal injury, the treatment of muscular dystrophies, and the treatment of lysosomal storage diseases, will all now be moved into active phases with the intention of identifying at least 3 candidate drugs to be made clinic-ready within 2 years.
$NVGN recent news/filings
bullish
## source: finance.yahoo.com
Tue, 28 Apr 2015 10:22:00 GMT ~ 6:22 am Novogen regains full compliance with Nasdaq listing rule
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nvgn
*********************************************************
Tue, 28 Apr 2015 03:48:00 GMT ~ Novogen Regains Full Compliance with NASDAQ Listing Rule
[PR Newswire] - NASDAQ: NVGN) (Company), announced today that it received a letter from NASDAQ informing it that it had regained full compliance with NASDAQ Listing Rule 5550(b) (Listing Rule).
read full: http://finance.yahoo.com/news/novogen-regains-full-compliance-nasdaq-034800625.html
*********************************************************
Mon, 27 Apr 2015 04:15:00 GMT ~ Novogen Posts Details on Rights Issue Offering for Shareholders
[PR Newswire] - NVGN: NASDAQ) (Company), announced last week that it lodged a prospectus with ASIC on 23 April 2015 relating to its pro rata non-renounceable rights issue (Offering). The prospectus has been posted on its website and notices to shareholders and optionholders have been dispatched as required under the ASX Listing Rules. Copies of the notices to shareholders and optionholders are available on the Company's website at www.novogen.com. This announcement intends to bring certain key matters and important dates to the attention of shareholders and to the market generally.
read full: http://finance.yahoo.com/news/novogen-posts-details-rights-issue-041500151.html
*********************************************************
Wed, 22 Apr 2015 02:27:00 GMT ~ Cantrixil Receives Orphan Drug Designation from FDA
[PR Newswire] - SYDNEY, April 21, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. Orphan Drug Designation is an important development for any experimental drug and has been instigated in a number of territories including the U.S, Europe and Australia to encourage the development of drugs for clinical indications that do not have a high incidence.
read full: http://finance.yahoo.com/news/cantrixil-receives-orphan-drug-designation-022700141.html
*********************************************************
Tue, 21 Apr 2015 15:52:00 GMT ~ Novogen (NVGN) Stock Falls Today on Private Placement
read full: http://www.thestreet.com/story/13120383/1/novogen-nvgn-stock-falls-today-on-private-placement.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
$NVGN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NVGN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NVGN/company-info
Ticker: $NVGN
OTC Market Place: Not Available
CIK code: 0001075880
Company name: Novogen Ltd.
Company website: http://www.novogen.com
Incorporated In: Australia
$NVGN share structure
## source: otcmarkets.com
Market Value: $510,992 a/o Apr 27, 2015
Shares Outstanding: 2,018,137 a/o Jan 03, 2011
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NVGN extra dd links
Company name: Novogen Ltd.
Company website: http://www.novogen.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVGN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/news - http://finance.yahoo.com/q/h?s=NVGN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Novogen+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Novogen+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Novogen+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.novogen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.novogen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.novogen.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001075880&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVGN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVGN
$NVGN DD Notes ~ http://www.ddnotesmaker.com/NVGN
Novogen Regains Full Compliance with NASDAQ Listing Rule
SYDNEY, April 28, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that it received a letter from NASDAQ informing it that it had regained full compliance with NASDAQ Listing Rule 5550(b) (Listing Rule).
In November 2014, the Company received a deficiency notice from NASDAQ, requesting the Company to submit a plan to regain compliance with the Listing Rule, which requires either (i) a minimum of $2,500,000 in stockholders' equity as of June 30, 2014; (ii) at least $35,000,000 market value of listed securities, or (iii) at least $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
Further to lodgement of its plan to regain compliance, NASDAQ granted an extension to the Company in January 2015.
The recent growth in the Company's market value, as well as the substantial increase of its assets with the current capital-raising program, has allowed the Company to regain compliance with the Listing Rule.
Graham Kelly, Novogen Group CEO and Executive Chairman, said, "Novogen regards itself as a joint US-Australian company. Roughly half of our shareholders are US residents. We have a joint venture company with one of the leading universities in the US. We are conducting increasing collaborations with leading US research institutions and hospitals as our drug technologies get better appreciated. The US eventually will be the leading market for our drug candidates. Maintaining our NASDAQ listing is vital to us."
Hot Copper post
Clearly the ground breaking and pivotal areas of investigation for Novogen centres around cancer treatment; but something which has flown under the radar is the non oncology areas of opportunity.
After research and conversations with Professor Graham Kelly, I’ve collated the 5 core areas of opportunity for Novogen.
Non Oncology Opportunity 1:
By way of background, within the Yale collaboration into TRXE-002, a curious observation was made; in very low doses, TRXE-002 stopped killing the cancer stem cells and started making them grow.
Clearly this news was met with angst and frustration, until it was discovered that the cancer stem cells started looking and behaving like normal stem cells.
This is now one of the matters Novogen and Feinstein are examining with great enthusiasm; having a drug with the ability to transform cancer cells into normal stem cells.
Which leads into the first non-oncology opportunity – whether Novogen can “make” other badly behaving stem cells behave "normally".
To do this Novogen is working with Sydney based Genea Biocells, who has a large library of stem cells extracted from human embryos carrying a range of genetic abnormalities. After screening different stem cells, the Yale observations (of being able to make badly behaving stem cells act normally), were validated within some of the compounds.
The compounds that show this effect have no anti-cancer activity.
This is a major achievement in itself, but leads into
Non Oncology Opportunity 2:
In collaboration with Genea Biocells, Novogen has a program currently running on a muscular dystrophy condition known as FSHD. A grant from the global FSHD Foundation has been granted, with the aim of finding SBP’s that have the ability to make affected muscle stem cells make normal muscle fibres.
Take a second to let that sink in. Developing a drug that will reverse the muscle wasting that goes with the different forms of muscular dystrophy. Professor Graham expressed that the team believe they are on the cusp of doing this.
Non Oncology Opportunity 3:
The next logical step was to see what other applications could be applied to the stem cell developments, which leads us to the brain.
Genea Biocells have normal embryonic brain stem cells and the objective was to see if it was possible to make these stem cells proliferate and produce fully mature brain cells.
Novogen identified three compounds with potent ability to do so, and all three are currently at the University of Melbourne being tested in an animal model of brain injury.
By way of background, brain stem cells are exceptionally slow and lazy at repairing brain injury, which is why stroke victims are slow to recover (can anyone else see where this is going, and the potentially massive market on just this one non oncology opportunity).
The aim is to be able to encourage brain stem cells to come to the site of the injury and stay long enough to repair the injury. Professor Graham has indicated that a read out of this study will be in 2 months time.
If this proves to be positive, Novogen will have an entirely novel approach to the problems of brain trauma, stroke and spinal injury.
Non Oncology Opportunity 4
Another program concerns a group of paediatric diseases known as lysosomal storage diseases. There are about 30 different conditions here, all genetic. One of them is SanFilippo Syndrome. Currently this is being treated with genistein, the same compound that is the heritage for the whole benzopyran family. We have a collaboration happening in Poland and the UK intended to identify the active pharmacophore.
Non Oncology Opportunity 5
Professor Graham is empathic that this opportunity is the big one – so I’ll take a bit of time to explain the details as much as I can.
There is a growing understanding of the role of a cell’s cytoskeleton; the cytoskeleton serves many functions, the main one being how a cell divides. 30 years ago the scientific world thought that the role of the cytoskeleton was fairly limited, with the main purpose being to give the cell its shape, its ability to move, and providing the means for the cell to divide.
The cytoskeleton is composed of two completely different structures:
microtubules (hollow structures)
[?IMG]
&
microfilaments (solid, rope-like structures)
[?IMG]
When a cell prepares itself to divide, the microtubules and the microfilaments combine to form a structure known as a mitiotic spindle.
[?IMG]
Here’s where things get interesting – the micotubules make up the main framework of the mitiotic spindle. The family of anti-miotic drugs has become the most widely prescribed drugs in chemotherapy because they stop the microtubules from forming the mitotic spindle.
The chromosomes attach to the microtubules via a structure known as the kinetochore. The kinetochore is composed of microfiliments; this is what Anisina targets and the combined effects of destroying both components is through to be behind the 20-fold increase in anti-cancer potency of the anti-miotic (chemo) family of drugs in animals what we see when we combine Anisina with them.
Now that we’ve got that clear, I can move on to the final opportunity (if the above is unclear, read through it a few times so the next part makes sense).
This opportunity relates to Novogen’s ATM technology platform, and the opportunity for a whole new range of therapeutics targeted to the cytoskeleton and it’s fundamental functions (cell signaling, glucose metabolism).
The cytoskeleton plays a role in virtually every aspect of cell function – they are the means by which signals are received and sent by the cell. It regulates the receptors on the cell’s surface and also plays a role in general metabolism such as glucose use and energy production; in short, the nucleus of the cell is the brain and the cytoskeleton is the body.
One of the many such areas of investigation, for example, is Ulcerative Coilitis (a form of IBD – Inflammatory Bowel Disease). Novogen has an advantage over anyone else in the field, they know how to target the microfilaments in a highly selective way; the microfilaments are made up of over 40 different forms of tropomyosin (known as isoforms), and Novogens expertise lies in building drugs, which block specific isoforms.
The pivotal part of this opportunity is as follows; Cancer is associated with the over-expression of one particular isoform, and that is what Anisina attacks, and that same isoform is implicated in Ulcerative Coilitis. Let that sink in for a moment.
It takes a few reading attempts to let the above sink in, but take the time to really digest it. Novogen believes that they will eventually identify other specific isoforms associated with almost all forms of degenerative disease, thus allowing the experience gained from developing Anisina to develop drugs for other specific indications.
In summary, in my eyes it makes perfect sense why Novogen have sought to raise money – they are embracing a platform approach to their offerings. It’s not simply “We have one drug and we are trying to make it work” – they have multiple offerings, all of which are actively being investigated.
If just one pays off, the current sub 100m market cap will seem a pittance.
Also, even the core offerings are spectacular – Anisina is a complementary drug to standard anti-miotics – it’s not in competition with the current suite of drugs.
Put simply, the aim is to prove that Anisina makes standard chemo better, more potent, with fewer side effects. If this is proven to be true, we’re looking at a company not in the millions, but the billions as a market cap.
Kelly explains these apparent conflicting observations through the Novogen theory that they have stumbled on a family of molecules that function in a housekeeping role in the cell, particularly the stem cell. Where the stem cell is behaving abnormally (either because it has developed mutations or has inherited a genetic fault), then this family of compounds have the ability either to correct the fault, or where correction is not possible, to kill the damaged cell. In the case of stem with normal, but tardy, function (as with brain stem cells), they appear to have the ability to stimulate them to lift their game.
Kelly says he believes that this discovery will revolutionise how we look at and how we treat many diseases.
The above is written with information provided from Professor Graham Kelly, and public domain information – it is not investment advice, and you should seek professional advice before making any investment decisions.
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
396
|
Created
|
10/19/07
|
Type
|
Free
|
Moderators |
Dr Graham Kelly, Executive Chairman
Novogen Enquiries
Dr Graham Kelly
CEO Novogen Group
Graham.Kelly@novogen.com
+(61 2) 9472 4100
Media Enquiries
Cristyn Humphreys
Operations Manager Novogen Group
Cristyn.Humphreys@Novogen.com
+ 61 2 9472 4111 / + 61 499 088 482
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |